IRLAB Therapeutics AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr0.13.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.81.
During the past 3 years, the average EBIT per Share Growth Rate was 14.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for IRLAB Therapeutics AB's EBIT per Share or its related term are showing as below:
OSTO:IRLAB A'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -39.5 Med: -9.8 Max: 14.3
Current: 14.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of IRLAB Therapeutics AB was 14.30% per year. The lowest was -39.50% per year. And the median was -9.80% per year.
OSTO:IRLAB A's 3-Year EBIT Growth Rate is ranked worse than 51.78% of 1178
companies
in the Biotechnology industry
Industry Median: 15.55
vs OSTO:IRLAB A: 14.30
IRLAB Therapeutics AB (OSTO:IRLAB A) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
IRLAB Therapeutics AB EBIT per Share Related Terms
IRLAB Therapeutics AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for IRLAB Therapeutics AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.81
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IRLAB Therapeutics AB (OSTO:IRLAB A) has a EBIT per Share of kr-0.81 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on IRLAB Therapeutics AB and its competitors. According to the industry distribution chart, IRLAB Therapeutics AB ranks #610 out of 1178 companies in the Biotechnology industry, placing it in the top 51.8%.
Is IRLAB Therapeutics AB's EBIT per Share too high?
IRLAB Therapeutics AB's current EBIT per Share is kr-0.81. Based on the distribution chart, IRLAB Therapeutics AB ranks #610 out of 1178 companies in the Biotechnology industry, which is below the industry midpoint. Overall, IRLAB Therapeutics AB has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IRLAB Therapeutics AB ranks #610 out of 1178 companies for EBIT per Share. This places IRLAB Therapeutics AB in the lower half of its industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on IRLAB Therapeutics AB and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IRLAB Therapeutics AB's current EBIT per Share is kr-0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.75, compared to a current price of kr1.29 — trading 89% below its estimated fair value. The current EBIT per Share is kr-0.81. IRLAB Therapeutics AB's overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current EBIT per Share is kr-0.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?
Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued.
The current stock price of kr1.29 is trading 89% below its estimated GF Value™ of kr11.75.
GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.
Key valuation signals for OSTO:IRLAB A:
EBIT per Share: kr-0.81
GF Value™: kr11.75 vs. price of kr1.29 (89% below fair value)
No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
36GF Score
Get the complete analysis for OSTO:IRLAB A
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IRLAB A has been successfully added to your 
